Wageningen Bioveterinary Research (WBVR) wants to improve the control of gut infections in animals by using non-antibiotics based alternatives. We are currently looking for innovative partners. Join us in finding answers together!
We believe that the prudent use of antibiotics is needed to control the widespread development and transfer of antimicrobial resistant bacteria. Therefore it is essential to improve and implement non-antibiotic alternatives such as organic acids, yeasts, probiotics and single domain antibodies (VHHs, nanobodies).
Do you share our vision on antibiotics? Do you want to work on finding non-antibiotic based alternatives together? Are you interested to know more and invest in our approach to control gastrointestinal infections in young animals, especially during transition periods? If the answer is yes, we would like to invite you to collaborate with us in a Public-Private-Partnership.
All interested industry/biotech are welcome to join us in this multi-year Public-Private-Partnership (PPP). The aim is to obtain government funding of 50% with 50% co-financing from our industry partners, over a period of max. 4 years.
Areas of interest
- Control gastrointestinal infections in young animals using non-antibiotics based alternatives
- Application of alternatives to antibiotics in drinking water (organic acids, yeasts, probiotics, antibodies)
- Passive immunotherapy utilising VHHs against gastrointestinal pathogens (E. coli, Campylobacters, Salmonella)
- Tailor-made intervention studies including evaluation of growth performance, microbiota composition and immunological markers
Do you have a different research focus?
Contact us to inquire if our expertise can be of use. We have the following know-how & technologies in-house:
- Antibiotic resistance
- Gut microbiota composition
- Single domain antibodies
- Animal models